Entries by
Meet our Scientific Advisory Board: Interview with John Jensen
John Jensen, PhD, Senior Scientist, Deputy Head of Department, Department of Bioscience, Aarhus University What is your field of expertise? Senior researcher within ecotoxicology and ecology with special interest in pharmaceuticals, having most practical experience in soil ecotoxicology and veterinary medicines, but also aspects of human medicinal products. Furthermore, I have 15+ years of experience […]
IMI funds a project to manage the environmental risks of medicines
The Innovative Medicines Initiative (IMI) has approved a 9.7 million euro project to contribute to a sustainable future by proactively managing the environmental impact of medicines. Lead by Radboud University Nijmegen and the pharmaceutical company AstraZeneca AB Ltd., PREMIER aims to deliver a framework for assessing and characterising the environmental risks of Active Pharmaceutical Ingredients […]
European Initiative to minimise the environmental impact of medicines
The Prioritisation and Risk Evaluation of Medicines in the Environment (PREMIER) Innovative Medicines Initiative (IMI) project will design a novel information and assessment system for identifying and addressing the environmental risks of medicines, especially for those with limited data availability. PREMIER will develop a centralised, user-friendly and transparent database accessible for all relevant stakeholders such […]
PREMIER welcomes ERA Data on APIs & API Testing Tips!
Share your environmental risk assessment (ERA) data & testing tips on active pharmaceutical ingredients (APIs) to help us build the world’s leading publicly available repository on ERA data for pharmaceuticals. PREMIER is currently collecting ERA data on APIs from a wide range of sources, e.g. industry partners, regulatory agencies and public literature. We will furthermore […]
